1 | i am a us | | | | | | | 6 | 0.75% |
2 | please find below the | | | | | | | 4 | 0.50% |
3 | – germany neuraceq® – | | | | | | | 4 | 0.50% |
4 | poland portugal spain sweden | | | | | | | 3 | 0.37% |
5 | of brain neuritic βamyloid | | | | | | | 3 | 0.37% |
6 | contact us at info | | | | | | | 3 | 0.37% |
7 | czech republic france germany | | | | | | | 3 | 0.37% |
8 | republic france germany iceland | | | | | | | 3 | 0.37% |
9 | neuraceq® – educational materials | | | | | | | 3 | 0.37% |
10 | please contact us at | | | | | | | 3 | 0.37% |
11 | portugal spain sweden united | | | | | | | 3 | 0.37% |
12 | neuraceq® reader training material | | | | | | | 2 | 0.25% |
13 | present in patients with | | | | | | | 2 | 0.25% |
14 | effects on the breastfed | | | | | | | 2 | 0.25% |
15 | kingdom please find below | | | | | | | 2 | 0.25% |
16 | spain sweden united kingdom | | | | | | | 2 | 0.25% |
17 | at lifemicom to register | | | | | | | 2 | 0.25% |
18 | by the local european | | | | | | | 2 | 0.25% |
19 | norway poland portugal spain | | | | | | | 2 | 0.25% |
20 | netherlands norway poland portugal | | | | | | | 2 | 0.25% |
21 | ireland italy netherlands norway | | | | | | | 2 | 0.25% |
22 | france germany iceland ireland | | | | | | | 2 | 0.25% |
23 | belgium czech republic france | | | | | | | 2 | 0.25% |
24 | product characteristics in different | | | | | | | 2 | 0.25% |
25 | of product characteristics in | | | | | | | 2 | 0.25% |
26 | approved by the local | | | | | | | 2 | 0.25% |
27 | training – germany neuraceq® | | | | | | | 2 | 0.25% |
28 | authorities neuraceq® – reader | | | | | | | 2 | 0.25% |
29 | neuraceq® in europe must | | | | | | | 2 | 0.25% |
30 | info at lifemicom to | | | | | | | 2 | 0.25% |
31 | at info at lifemicom | | | | | | | 2 | 0.25% |
32 | us at info at | | | | | | | 2 | 0.25% |
33 | to one of the | | | | | | | 2 | 0.25% |
34 | a reader training please | | | | | | | 2 | 0.25% |
35 | one of the upcoming | | | | | | | 2 | 0.25% |
36 | in europe must undergo | | | | | | | 2 | 0.25% |
37 | of neuraceq® in europe | | | | | | | 2 | 0.25% |
38 | neuraceq® – reader training | | | | | | | 2 | 0.25% |
39 | use of neuraceq® in | | | | | | | 2 | 0.25% |
40 | the use of neuraceq® | | | | | | | 2 | 0.25% |